⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Immuno-senolytics
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-12 — The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells: cross-connection with senolytics: [mechanism-plausible] The reported DNA damage response–PD-L1 pathway connects senescent-cell persistence to immune-checkpoint targeting as a proposed alternative to direct senolytic killing, without supplied intervention outcome evidence. (novelty: 3)
- 2026-09-29 — uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor: cross-connection with upar-bispecific-tce-senolytic: GFD-CD3 extends the immuno-senolytic class into non-human primates with serum aminotransferases proposed as a translational safety biomarker — a concrete clinical-chemistry monitoring handle that prior immuno-senolytic concepts have lacked. (novelty: 4)
- 2026-10-01 — Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.: cross-connection with rapamycin-mtor: Rapamycin lowering senescent-leukocyte transcriptional signatures in aged atherosclerotic mice overlaps with immuno-senolytic goals of clearing/retuning senescent immune cells; the two strategies converge on vascular immunoaging. (novelty: 3)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: cross-connection with upar-bispecific-tce-senolytic: Adds a bispecific T-cell engager modality to the immuno-senolytic class alongside CAR-T and checkpoint approaches like PD-L2 blockade. (novelty: 4)
- 2026-09-23 — Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.: cross-connection with birc6-inhibition: Both strategies exploit apoptosis-resistance in aged/senescent cells — BIRC6 inhibition removes an anti-apoptotic shield on aged HSCs, conceptually parallel to senolytic clearance of apoptosis-resistant senescent cells. (novelty: 4)
- 2026-09-10 — Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.: cross-connection with pd-l2-blockade: PD-L2 blockade fits the immuno-senolytic paradigm, joining CAR-T and vaccine approaches by using immune effectors to clear senescent cells — here via checkpoint disinhibition rather than engineered targeting. (novelty: 4)
- 2026-06-12 — Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.: cross-connection with car-t-senolytics: CAR T senolytics are a specific engineered arm of the broader immuno-senolytic strategy (which also includes NK-cell and vaccine approaches to senescent-cell clearance), sharing the goal of using adaptive/innate immunity for durable clearance rather than repeated small-molecule dosing. (novelty: 3)
- 2026-07-16 — Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation.: cross-connection with cgas-targeting-therapeutics: Macrophage-targeted cGAS blockade and immuno-senolytics converge on senescent/inflammatory myeloid cells as the effector population driving systemic aging, offering complementary levers (silence the cGAS driver vs. clear the cell). (novelty: 3)
Open questions
Related
Contributing findings
Cleaning, Chasing and Calming: Promising Paradigms of Senotherapy in Aging-Related Diseases.
20-jul-2026
novelty 2
per-area 3
introduces